Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab as second-line treatment for immune thrombocytopenic purpura
2005-005918-20Phase 3Completed
- Sponsor
- Rikshospitalet
- Start
- Oct 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in immune thrombocytopenia (ITP) (2 arms), sponsored by Rikshospitalet. Primary endpoint: Splenectomy during follow-up after randomisation. Started Oct 2008; status: completed.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2005-005918-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005918-20.